Daslemia 100mg Tablet

3499.0 INR (Approx.)

3416 INR (Approx.)

30 Tablets

10 strips per box

Dasatinib 100 mg

Cefuroxime Axetil 500mg Clavulanic Acid 125mg

Daslemia 100 contains Dasatinib 100 mg, a potent targeted tyrosine kinase inhibitor produced by Intas Pharmaceuticals Ltd. It is widely prescribed for the management of Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Daslemia 100 acts by blocking targeted abnormal proteins that signal cancer cells to multiply. Manufactured in WHO-GMP compliant facilities, this product offers high bioequivalence and efficacy. Available in a pack of 30 tablets for international pharma distributors, hospital procurement, and wholesale export supply.Product Features:High efficacy oral targeted therapy formulation.Formulated in compliance with international quality and manufacturing standards.Moisture-sealed packaging to preserve stability and shelf-life.Manufactured by Intas Pharmaceuticals, a global healthcare leader.Applications:First-line treatment for adults with newly diagnosed chronic phase Ph+ CML.Treatment of post-imatinib resistant or intolerant Ph+ CML in adult patients.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).Daslemia 100 contains Dasatinib 100 mg, a potent targeted tyrosine kinase inhibitor produced by Intas Pharmaceuticals Ltd. It is widely prescribed for the management of Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Daslemia 100 acts by blocking targeted abnormal proteins that signal cancer cells to multiply. Manufactured in WHO-GMP compliant facilities, this product offers high bioequivalence and efficacy. Available in a pack of 30 tablets for international pharma distributors, hospital procurement, and wholesale export supply.Product Features:High efficacy oral targeted therapy formulation.Formulated in compliance with international quality and manufacturing standards.Moisture-sealed packaging to preserve stability and shelf-life.Manufactured by Intas Pharmaceuticals, a global healthcare leader.Applications:First-line treatment for adults with newly diagnosed chronic phase Ph+ CML.Treatment of post-imatinib resistant or intolerant Ph+ CML in adult patients.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Dasatinib

Cefuroxime Axetil and Clavulanic Acid

Other

Other, Treatment of bacterial infections

As prescribed by physician

As Directed By The Physician

As prescribed by the physician

Adults

Adults and children above 12 years of age, Other

Store in a cool, dry place

Cool and dry place

Store in a cool and dry place below 25AdegC away from direct sunlight and moisture